-
Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline
•
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has exercised its options within a research, option, and licensing agreement to utilize Biocytogen’s fully human antibodies. This move is aimed at bolstering Adcendo’s antibody drug conjugate (ADC) pipeline. Adcendo’s Focus on First-In-Class ADCsAdcendo is a…
-
Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline
•
Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed Series B financing round, raising USD135 million. The proceeds from this round will be utilized to accelerate the development of its first-in-class ADC pipeline, which includes the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05,…
-
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
•
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody drug conjugates (ADCs) within an existing deal with China’s Duality Biologics. This move follows Adcendo’s initial licensing agreement in January 2023, which granted access to Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload platform for…
-
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
•
Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality’s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program.…
